MetaCap

BioVie (BIVI) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed Quantum Biopharma (QNTM) over the past year, losing 38.2% versus a loss of 77.6%. Over five years, QNTM leads with a -98.5% price change compared with -99.9% for BIVI. BioVie is the larger company by market cap ($8.6 million vs $8.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-38.22%QNTM-77.60%
+107%+10%-86%
Nov 21, 20251 yearNov 20, 2026
BIVI-99.86%QNTM-98.66%
+138%+13%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus QNTM key metrics
MetricBIVIQNTM
Share price$0.80$1.29
Market cap$8.58M$8.29M
1-day change-12.07%-9.15%
YTD return-31.03%-82.33%
1-year return-38.22%-77.60%
5-year return-99.87%-98.51%
EPS (TTM)$-2.85$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.07M—
52-week high$3.79$12.42
52-week low$0.7515$1.26
Distance from 52-week high-78.89%-89.61%
Analyst consensusnonenone
Avg. price target upside+557.50%+851.16%
Average volume568.61K148.83K
Shares outstanding10.72M6.43M
Employees13—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed QNTM by 39.4 percentage points over the past year.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

BIVI vs QNTM FAQ

Which is bigger, BioVie or Quantum Biopharma?

BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.29M for Quantum Biopharma (QNTM).

Which stock has performed better over the past year, BIVI or QNTM?

BIVI returned -38.22% over the past 12 months, compared with -77.60% for QNTM (price return, excluding dividends). Past performance does not predict future results.

Are BioVie and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons